Menu
Search
|

Menu

Close
X

CRISPR Therapeutics AG CRSP.OQ (NASDAQ Stock Exchange Global Market)

36.48 USD
-- (--)
As of Nov 13
chart
Previous Close 36.48
Open --
Volume --
3m Avg Volume 273,734
Today’s High --
Today’s Low --
52 Week High 73.90
52 Week Low 16.71
Shares Outstanding (mil) 40.59
Market Capitalization (mil) 783.42
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.36 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY18
3
FY17
41
FY16
5
FY15
0
EPS (USD)
FY18
-2.506
FY17
-1.557
FY16
0.382
FY15
-0.642
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
76.97
5.95
Price to Book (MRQ)
vs sector
3.91
4.89
Price to Cash Flow (TTM)
vs sector
--
22.90
Total Debt to Equity (MRQ)
vs sector
0.00
17.74
LT Debt to Equity (MRQ)
vs sector
0.00
13.15
Return on Investment (TTM)
vs sector
-16.50
14.22
Return on Equity (TTM)
vs sector
-56.05
15.99

EXECUTIVE LEADERSHIP

Rodger Novak
Chairman of the Board of Directors, President, Founder, Since 2017
Salary: $356,242.00
Bonus: $118,424.00
Samarth Kulkarni
Chief Executive Officer, Director, Since 2018
Salary: $145,833.00
Bonus: $43,750.00
Kala Subramanian
Senior Vice President - Strategic Development and Operations, Since 2016
Salary: --
Bonus: --
Megan Wherry Menner
Senior Vice President of Human Resources, Since
Salary: --
Bonus: --
Sven Lundberg
Chief Scientific Officer, Since 2015
Salary: $302,605.00
Bonus: $90,928.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Baarerstrasse 14
ZUG   ZUG   6300

Phone: +4141.5613277

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.

SPONSORED STORIES